Sandbox vidit3: Difference between revisions
No edit summary |
No edit summary |
||
(4 intermediate revisions by the same user not shown) | |||
Line 263: | Line 263: | ||
==Order labs and tests== | ==Order labs and tests== | ||
❑ [[EKG]] ''(most important initial test)'' | |||
: ❑ [[Myocardial infarction]] | : ❑ [[Myocardial infarction]] | ||
: ❑ [[Tachyarrhythmia]] | : ❑ [[Tachyarrhythmia]] | ||
Line 280: | Line 280: | ||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box7" style="background: #B8B8B8; padding: 5px 10px;"> | <div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box7" style="background: #B8B8B8; padding: 5px 10px;"> | ||
==Order imaging studies== | ==Order imaging studies== | ||
Line 295: | Line 294: | ||
==Confirm diagnosis of syncope== | ==Confirm diagnosis of syncope== | ||
''Must have this 3 characteristics:'' <br> ❑ Short duration <br> ❑ Rapid onset <br> ❑ Complete spontaneous recovery | |||
</div> | </div> | ||
Line 302: | Line 301: | ||
==Diagnostic criteria== | ==Diagnostic criteria== | ||
❑ '''Cardiovascular''' | ❑ '''Cardiovascular''' | ||
: ❑ [[Arrhythmia]] and cardiac ischemia-related [[syncope]] is diagnosed by [[EKG]] specific findings ([[ESC#Classes of Recommendations|Class I; Level of Evidence: C]]) | : ❑ [[Arrhythmia]] and cardiac ischemia-related [[syncope]] is diagnosed by [[EKG]] specific findings ([[ESC#Classes of Recommendations|Class I; Level of Evidence: C]]) | ||
Line 315: | Line 313: | ||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box12" style="background: #B8B8B8; padding: 5px 10px;"> | <div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box12" style="background: #B8B8B8; padding: 5px 10px;"> | ||
===Risk stratification=== | |||
---- | ---- | ||
'''Determine if there are any high risk criteria:''' <br> ❑ Severe [[structural heart disease]] <br> ❑ [[CAD]]<br> ❑ Clinical or [[ECG]] features suggesting arrhythmic syncope: <br> | '''Determine if there are any high risk criteria:''' <br> ❑ Severe [[structural heart disease]] <br> ❑ [[CAD]]<br> ❑ Clinical or [[ECG]] features suggesting arrhythmic syncope: <br> | ||
Line 334: | Line 332: | ||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box13" style="background: #B8B8B8; padding: 5px 10px;"> | <div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box13" style="background: #B8B8B8; padding: 5px 10px;"> | ||
==Consider | |||
==Consider additional tests== | |||
❑ [[Stool guaiac test]] (rule out [[GI bleeding]]) <br> ❑ Blood and urine toxicology tests (rule out [[intoxication]]) | |||
</div> | </div> | ||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box16" style="background: #B8B8B8; padding: 5px 10px;"> | <div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box16" style="background: #B8B8B8; padding: 5px 10px;"> | ||
==Consider alternative diagnoses:== | ==Consider alternative diagnoses:== | ||
<br> | <br> | ||
Line 384: | Line 368: | ||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box18" style="background: #B8B8B8; padding: 5px 10px;"> | <div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-box18" style="background: #B8B8B8; padding: 5px 10px;"> | ||
==Recurrent syncopes== | ==Recurrent syncopes== | ||
Cardiac or neurally mediated tests as appropriate: <br> ❑ Holter if > 1 episode/week ([[ESC#Classes of Recommendations|Class I; Level of Evidence: B]]). <br> ❑ [[External loop recorder]] (ELR) if interval between episodes < 4 weeks ([[ESC#Classes of Recommendations|Class IIa; Level of Evidence: B]]). <br> ❑ [[Carotid sinus massage]] in patients > 40 years with uncertain syncopal etiology ([[ESC#Classes of Recommendations|Class I; Level of Evidence: B]]). <br> | |||
: <span style="font-size:85%;color:red"> Contraindicated in patients with previous [[TIA]] or [[stroke]] in the past 3 months. <br> Contraindicated in patients with [[carotid bruits]]. </span> | : <span style="font-size:85%;color:red"> Contraindicated in patients with previous [[TIA]] or [[stroke]] in the past 3 months. <br> Contraindicated in patients with [[carotid bruits]]. </span> | ||
</div> | </div> |
Latest revision as of 18:34, 26 March 2014
New
Click on boxes to expand/collapse detailed information.
|
Characterize symptoms❑ Loss of consciousness (LOC)
❑ Prodrome:
❑ Chest pain (suggestive of cardiovascular syncope)
❑ Activity prior to LOC: (suggestive of cardiovascular or reflex syncope)
❑ Bowel or bladder incontinence (suggestive of reflex syncope) Inquire about medications intake:❑ Nitrates
Obtain a detailed past medical history:❑ Previously healthy
❑ Cardiovascular disease:
❑ Neurological diseases: ❑ Metabolic disorders (diabetes) ❑ Recent trauma
Identify possible triggers:Suggestive of reflex syncope Suggestive of cardiovascular or orthostatic hypotension
Examine the patientVitals
Respiratory Cardiovascular
Neurologic
❑ Glasgow coma scale
Order labs and tests❑ EKG (most important initial test)
❑ Glucose (rule out hypoglycemia)
Confirm diagnosis of syncopeMust have this 3 characteristics:
Diagnostic criteria❑ Cardiovascular
❑ Orthostatic hypotension (OH)
❑ Reflex
Risk stratificationDetermine if there are any high risk criteria:
❑ Important comorbidities:
Consider additional tests❑ Stool guaiac test (rule out GI bleeding) Consider alternative diagnoses:
❑ Immediate in-hospital monitoring (in bed or telemetry) to look for abnormalities suggestive of arrhythmic syncope (Class I; Level of Evidence: B). Recurrent syncopesCardiac or neurally mediated tests as appropriate:
Diagnostic criteria❑ Induction of reflex hypotension or bradycardia with reproduction of syncope is diagnostic for reflex syncope (Class I; Level of Evidence: B). |
Drug | Adult dosage |
---|---|
Inhaled Short Acting β Agonists (SABA) | |
Albuterol/Bitolterol/Pirbuterol a) Nebulizer solution b) MDI | ♦ 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed or 10-15 mg/hour continuously. ♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed. |
Levalbuterol a) Nebulizer solution b) MDI | ♦ 1.25-2.5 mg every 20 mins for 3 doses, then 1.25-5 mg every 1-4 hours as needed. ♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed. |
Anticholinergics | |
Ipratropium bromide a) Nebulizer solution b) MDI | ♦ 0.5 mg every 20 mins for 3 doses, then as needed. ♦ 8 puffs every 20 mins as needed for upto 3 hours. |
Ipratropium with albuterol a) Nebulizer solution (each 3 ml containing 0.5 mg ipratropium and 2.5 mg albuterol) b) MDI (each puff contains 18 mcg ipratropium and 90 mcg albuterol) | ♦ 3 ml every 20 mins for 3 doses, then as needed. ♦ 8 puffs every 20 mins as needed for 3 hours |
Systemic corticosteroids | |
Prednisone/Prednisolone/Methylprednisolone | ♦ 40-80 mg/day in 1 or 2 divided doses until peak expiratory flowrate (PEF) reaches 70% of personal best. |
Clinical course | Unstable |
---|---|
Physical examination | Signs of heart failure |
Functional class | IV |
6MWD | Less than 400 m |
Echocardiogram | RV Enlargement |
Hemodynamics | RAP high CI low |
BNP | Elevated/Increasing |
Treatment | Intravenous prostacyclin and/or combination treatment |
Frequency of evaluation | Q 1 to Q 3 months |
FC assessment | Every clinic visit |
6MWT | Every clinic visit |
Echocardiogram2 | Q 6 to Q 12 months/center dependent |
BNP | center dependent |
RHC | Q 6 to Q 12 months or clinical deterioration |